Role of Follistatin during Androgen Regulation of Body Composition

描述（由申请人提供）：在各种临床试验中，睾酮(T)补充剂增加肌肉量并减少脂肪量，试验对象包括健康的年轻男性、性腺功能低下的男性和血清T水平低的老年男性。然而，T调节机体组成的分子机制尚不清楚。我们发现，T通过雄激素受体（AR）介导的途径增加间充质多能细胞的肌肉量和减少脂肪量，并激活脂肪前细胞的AR/ β -连环蛋白/ tgf -4途径，抑制与卵泡抑素（Fst）上调相关的脂肪形成。我们假设T在体外和体内激活AR/ β -catenin/TCF-4通路，激活Fst，通过抑制Mst/ tgf - β信号调节机体成分。我们将采用两种经过验证的成人间充质干细胞体外模型来测试T和DHT是否首先通过激活AR/ β -catenin/TCF-4通路来激活f_1来调节细胞分化，而SiRNA抑制β -catenin则可以消除这些作用。我们将通过免疫沉淀确定AR、β -连环蛋白和TCF-4之间的相互作用，并通过免疫荧光和细胞分离确定它们的核易位。使用TCF-4荧光素酶报告基因法检测TCF-4在雄激素作用下的转录激活。我们将通过上调Fst来确定这些雄激素是否抑制体外tgf - β /Mst信号。我们将在体外测试T和DHT是否抑制Mst生物活性、Smad2/3磷酸化和Smad7激活，以及通过Fst SiRNA或使用抗Fst抗体抑制Fst水平是否会阻断这些雄激素对肌分化的影响。我们将研究去势诱导对C57/BL6J小鼠体成分的影响是否伴随着Fst水平的平行下降，并且在这些被去势的小鼠中补充T或重组卵黄素能显著阻断去势诱导对无脂质量和整体体成分的影响。这些研究将为雄激素作用机制提供新的见解，并与Fst单独应用或与低剂量T联合应用直接相关，用于治疗艾滋病毒和衰老相关的肌肉损失，因为高生理上剂量的T与其多效性作用相关，包括通过提高前列腺特异性抗原增加前列腺癌的风险。

DESCRIPTION (provided by applicant): Testosterone (T) supplementation increases muscle mass and decreases fat mass in a variety of clinical trials using healthy young men, hypogonadal men, and in older men with low serum T levels. However, the molecular mechanisms by which T regulates body composition are not well known. We identified that T increases muscle mass and decreases fat mass in mesenchymal multipotent cells via androgen receptor (AR)-mediated pathway and activates AR/beta-catenin/TCF-4 pathway in preadipocyte cells to inhibit adipogenesis that was associated with up-regulation of follistatin (Fst). We hypothesize that T activates AR/beta-catenin/TCF-4 pathway both in vitro and in vivo to activate Fst, which regulates body composition by inhibiting Mst/TGF-beta signaling. We will employ two validated in vitro models of adult, mesenchymal stem cells to test whether T and DHT activate Fst via activation of AR/beta-catenin/TCF-4 pathway to regulate cell differention, and inhibition of beta-catenin by SiRNA abolishes these effects. We will determine the interaction between AR, beta-catenin, and TCF-4 by immunoprecipitation and their nuclear translocation by immunofluorescence and cell fractionation. TCF-4 transcriptional activation in response to androgen will be measured by using TCF-4 luciferase reporter assay. We will determine whether these androgens inhibit TGF-beta/Mst signaling in vitro through up-regulation of Fst. We will test whether T and DHT inhibit Mst bioactivity, Smad2/3 phosphorylation and activate Smad7 in vitro and inhibition of Fst levels either by Fst SiRNA or use of anti-Fst antibody blocks the effects of these androgens on myogenic differentiation. We will investigate whether castration-induced effects on body composition in C57/BL6J mice are accompanied by parallel decrease in Fst levels and supplementation of T or recombinant follistatin in these castrated mice significantly block castration-induced effects on fat-free mass and overall body composition. These studies will provide novel insights into the mechanisms of androgen action and have direct relevance to the application of either Fst alone or in combination of low doses of T for the treatment of HIV and aging-associated muscle loss as high supraphysiological doses of T are associated with its pleotropic effects including increased risk of prostate cancer by elevating prostate-specific antigen.